Skip to main content
SpringerLink
Log in

Metastasiertes Nierenzellkarzinom unter Bevacizumab als Erstlinientherapie

Progressionsfreies Überleben seit 3 Jahren

Bevacizumab as first-line therapy in metastatic renal cell carcinoma

Progression-free survival for 3 years

  • Kasuistiken
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Wir berichten über den Fall einer 72-jährigen Patientin, die im Jahr 2006 aufgrund eines Nierenzellkarzinoms (NZK) einer Tumornephrektomie (klarzelliges NZK Grad II nach Fuhrmann, Stadium pT3a,R0) unterzogen wurde. Im Laufe der Jahre wurden mehrere chirurgische und radiologische Interventionen aufgrund von verschiedenen metastatischen Läsionen durchgeführt. Dieser Fallbericht beschreibt ein progressionsfreies Überleben unter Bevacizumab in der Erstlinien Therapie seit 3 Jahren. Mit Ausnahme der Hypertonie leidet die Patientin bisher an keinen weiteren Nebenwirkungen der Bevacizumab-Therapie.

Abstract

We report the case of a 72-year-old woman who was diagnosed in 2006 with renal cell cancer (RCC) and had undergone consecutive tumor nephrectomy (clear-cell RCC, Fuhrmann grade II, stage pT3a, R0). Over the years, the patient underwent several surgical and radiological interventions due to various metastatic lesions. This case report describes the 3-year progression-free survival in a patient who underwent first-line therapy with the monoclonal antibody bevacizumab. Except for hypertension, the patient does not suffer currently from any other side effects of bevacizumab therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297–301

    CAS  PubMed  Google Scholar 

  2. Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924

    Article  PubMed  Google Scholar 

  3. Thomas AZ, Adibi M, Borregales LD et al (2015) Surgical management for local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. J Urol pii: S0022-5347(15)03271-1. doi:10.1016/j.juro.2015.02.2943

    Google Scholar 

  4. Alt AL, Boorjian SA, Lohse CM et al (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882

    Article  PubMed  Google Scholar 

  5. Brinkmann OA, Semik M, Gosherger G et al (2007) The role of residual tumor resection in patients with metastatic renal cell carcinoma and partial remission following immunotherapy. Eur Urol 6(Suppl):641–645

    Article  Google Scholar 

  6. Petralia G, Roscigno M, Zigeuner R et al (2010) Complete metastasectomy is an independent predictor of cancer-specific survival in patients with clinically metastatic renal cell carcinoma. Eur Urol 9(Suppl):162

    Article  Google Scholar 

  7. Staehler M, Kruse J, Haseke N et al (2009) Metastasectomy significantly prolongs survival in patients with metastatic renal cancer. Eur Urol 8(Suppl):181

    Article  Google Scholar 

  8. Escudier B, Plszanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111

    Article  PubMed  Google Scholar 

  9. Escudier B, Bellmunt J, Négrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150

    Article  CAS  PubMed  Google Scholar 

  10. Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422–5428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hurwitz HI, Douglas PS, Middleton JP et al (2013) Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 18(3):273–280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Feliu J, Salud A, Safont MJ et al (2015) Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 10(1):e0116527

    Article  PubMed  PubMed Central  Google Scholar 

  14. Vredenburgh JJ, Desjardins A, Herndon JE II et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259

    Article  CAS  PubMed  Google Scholar 

  15. Melichar B, Bracarda S, Matveev V, BEVLiN Investigators et al (2013) A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol 24(9):2396–2402

    Article  CAS  PubMed  Google Scholar 

  16. Ravaud A, Barrios CH, Alekseev B et al (2015) RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alfa-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol pii: mdv170 (Epub ahead of print)

    Google Scholar 

  17. Yang JC (2004) Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10(18 Pt 2):6367–63670

    Article  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. R. Pichler, W. Horninger, F. Aigner und I. Heidegger geben an, dass kein Interessenkonflikt besteht. Alle im vorliegenden Manuskript beschriebenen Untersuchungen am Menschen wurden mit Zustimmung der zuständigen Ethik-Kommission, im Einklang mit nationalem Recht sowie gemäß der Deklaration von Helsinki von 1975 (in der aktuellen, überarbeiteten Fassung) durchgeführt. Von allen beteiligten Patienten liegt eine Einverständniserklärung vor.

Author information

Authors and Affiliations

  1. Universitätsklinik für Urologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich

    R. Pichler FEBU, W. Horninger & I. Heidegger

  2. Universitätsklinik für Radiologie, Medizinische Universität Innsbruck, Innsbruck, Österreich

    F. Aigner

Authors
  1. R. Pichler FEBU
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Horninger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Aigner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Heidegger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Pichler FEBU.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pichler, R., Horninger, W., Aigner, F. et al. Metastasiertes Nierenzellkarzinom unter Bevacizumab als Erstlinientherapie. Urologe 55, 381–385 (2016). https://doi.org/10.1007/s00120-015-3976-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-015-3976-z

Schlüsselwörter

Keywords

Search

Navigation